Background/Aims: Programmed death receptor 1 (PD-1) is a promising new target for treatment of patients with hepatocellular carcinoma (HCC). A high expression level of programmed death-ligand 1 (PD-L1) is a possible prognostic indicator for poor outcome in other malignancies. Here, we investigated the clinical significance of PD-1 and PD-L1 in patients with HCC.
https://www.e-jlc.org/ grammed death-ligand 1 (PD-L1) and programmed deathligand 2 (PD-L2). 3 PD-L1 is expressed by tumor cells and is up-regulated in several malignancies. 2, [4] [5] [6] The interaction of PD-1 with PD-L1 results in the suppression of antitumor adaptive responses and immune escape of tumor cells. [7] [8] [9] This ultimately leads to poor prognosis in patients with malignancies. The blockade of immune checkpoints using monoclonal antibodies targeting the PD-1/PD-L1 pathway has shown promising results, especially in advanced solid tumors. 10 Elevated levels of soluble PD-L1 have been associated with poor prognosis in patients with renal cell carcinoma and in those with multiple myeloma. 11, 12 Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and its incidence is increasing. 13 In patients with advanced HCC, the few options for treatment include sorafenib and regorafenib. The results of clinical trials targeting the PD-1 axis in HCC have been recently reported. 14 The objective response rate was 20% and 15% in patients treated with nivolumab in phase 1/2 dose-expansion and dose-escalation phases. 14 In contrast, anti-PD-1 with nivolumab produced a disease control rate of 81.8%, with an objective response rate of 63.6% in patients with advanced HCC. 15 The prognostic role of PD-1/PD-L1 in HCC is not well understood. One study showed that high expression of PD-L1 was associated with poor outcome in patients with HCC. 1, 16 In contrast, PD-L1 expression was not correlated directly with the survival of patients in the surgery alone group. 17 Thus, in patients with HCC, questions remain of whether PD-L1 levels in tissue (tPD-L1) are correlated with serum PD-L1 (sPD-L1)/serum PD-1 (sPD-1) levels, and whether a correlation exists with prognosis.
In this study, we investigated the levels of tPD-L1, sPD-L1, and sPD-1 in samples from patients with HCC. In addition, we aimed to evaluate the clinical significance of PD-1 and PD-L1 levels in patients with HCC.
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Patients
We enrolled patients with HCC who underwent surgical resection between 2012 and 2017 at Severance Hospital, Seoul, Korea. The diagnosis of HCC was made according to current guidelines, 18 and matched tissue and serum samples were obtained from patients. The exclusion criteria were age ≤18 years, history of malignancy other than HCC, and history of liver transplantation. Ten serum samples from a healthy control cohort were retrieved from Yonsei Liver Blood Bank.
In addition, serial serum samples were collected from 9 patients with HCC undergoing nivolumab treatment. Patients received 240 mg nivolumab intravenously every 2 weeks. 
Collection of tissue and blood samples
The tissue and blood specimens were obtained from a biobank at Severance Hospital, Seoul, Korea. Primary HCC tissues (n=78) and matching non-neoplastic tissue were collected immediately following surgery and stored at -80℃ until processing and use. On the day of surgery, blood samples were obtained from each patient. The serum was obtained by centrifugation (3,000×g for 10 minutes) and stored at -80℃ until analysis.
Immunohistochemistry and Enzyme-Linked
Immunosorbent Assay (ELISA) assay The expression levels of PD-L1 in HCC tissues were scored. Scores were determined based on the percentage of positively stained immunoreactive cells and the staining intensity in tumor cells (score 1, no staining; score 2, <10% and weak staining; score 3, 10-50% and moderate staining;
and score 4, >50% and strong staining; Fig. 1 ). 16 The serum samples were assayed by using commercially available ELISA kits for PD-1 and PD-L1 (Invitrogen, Corp., Carlsbad, CA, USA), following the manufacturer's protocol.
Briefly, 96-well plates were incubated with standards at different concentrations, and serum samples were incubated for 
Statistical analyses
Continuous data are presented as median values (Q1-Q3),
and categorical data are presented as counts and percentages. pg/mL). No difference was found between sexes. A positive correlation was detected between tPD-L1 and sPD-1 in patients with HCC (R 2 =0.430, P<0.001). The median sPD-1 level increased linearly with the tPD-L1 score (P =0.002; Fig. 2 ). Values are presented as median (Q1-Q3) or number (%) NASH, nonalcoholic steatohepatitis; Pt, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein; tPD-L1, PD-L1 levels in tissue; sPD-L1, PD-L1 in serum; sPD-1, PD-1 in serum; PD-1, programmed death-ligand 1. nificant difference was observed in the baseline characteristics, except for the tPD-L1 score in patients with and without liver-related mortality ( Table 2 ). The tPD-L1 scores were significantly higher in patients who died than in those who survived (tPD-L1 score ≥3, 100% vs. 71.9%, P=0.035). HCC recurred in eight (10.3%) patients during the followup. No difference was observed between patients with and without HCC recurrence (Table 3 ). In addition, no significant association was observed between the sPD-L1/sPD-1 level and recurrence of HCC (data not shown). Values are expressed as mean±standard deviation, median (Q1-Q3), or number (%). NASH, nonalcoholic steatohepatitis; Pt, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein; tPD-L1, PD-L1 levels in tissue; sPD-L1, PD-L1 in serum; sPD-1, PD-1 in serum; PD-1, programmed death-ligand 1; PVI, portal vein invasion; HVI hepatic vein invasion; MVI, microvascular invasion.
Liver-related mortality and recurrence of HCC
Immunohistochemical analysis of TIL
https://www.e-jlc.org/ CD8+ lymphocytes and was the same as the correlation between PD-L1 expression and CD3+ lymphocytes (Supplementary Fig. 1 ).
Independent factors for survival in patients with HCC
A multivariate analysis showed that higher sPD-L1 levels (cut-off value, ≥19.2 pg/mL) tended to be associated with liver-related mortality (hazard ratio [HR], 6.866; 95% confidence interval, 0.804-58.659), but this association did not reach statistical significance (P =0.078; Table 4 ).
Changes of sPD-1 level in patients with advanced HCC treated with nivolumab
Serially collected serum samples from a total of nine patients with advanced HCC who received nivolumab treatment were included for analysis (Supplementary Table 1 ).
The median age was 60.0 years, and male sex predominated (88.9%). All patients had extrahepatic metastasis. The mean number of nivolumab administrations was 9.4 (range, 6-13). Values are presented as mean±standard deviation, median (Q1-Q3), or number (%). HCC, hepatocellular carcinoma; NASH, nonalcoholic steatohepatitis; Pt, prothrombin time; INR, international normalized ratio; AFP, alphafetoprotein; tPD-L1, PD-L1 levels in tissue; sPD-L1, PD-L1 in serum; sPD-1, PD-1 in serum; PD-1, programmed death-ligand 1; PVI, portal vein invasion; HVI, hepatic vein invasion; MVI, microvascular invasion.
The changes in PD-1 are shown in Fig. 3 . Of the patients who responded to nivolumab treatment, the best responses during the treatment were categorized as partial response (PR; n=2, 22.2%), stable disease (SD; n=3, 33.3%), and progressive disease (PD; n=4, 44.5%). Except for one of the five favorable therapeutic responses, a reduction of sPD-1 by ≥ 50% compared with baseline was observed immediately after nivolumab administration. One of the favorable therapeutic responses showed a serial decrease after 9 doses but eventually showed PD. The final responses were PR and SD in one patient each after the administration of 12 doses, and these patients ultimately developed PD. However, no change in the sPD-L1 level that matched the therapeutic response was observed ( Supplementary Fig. 2 ). No strong biomarker predicting postoperative outcome in HCC has been identified. In some studies, a preoperative serum AFP level (>400 ng/mL) was an independent prognostic factor for postoperative HCC survival. 19, 20 However, in our study, higher AFP level (>400 ng/mL) was not associated with prognosis in patients with HCC. In addition, we found no correlation between the AFP and PD-L1/PD-1 levels (data not shown). PD-L1 expression has been associated with poor prognosis in malignancies, including melanoma, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, renal cell cancer, and ovarian cancer. 21 Our study had several strengths. First, we measured the levels of PD-L1 in tissues and PD-L1/PD-1 in sera and investigated their association. Second, PD-1/PD-L1 level was checked in a small number of patients, but these reference values can be used for future research. Third, sera from patients who received anti-PD-1 treatment were collected serially, and the relationship of levels therein to prognosis was investigated. Lastly, we found that the PD-L1/PD-1 levels changed based on the circumstances and enhanced immune responses against tumors. However, we confirmed that the PD-L1/PD-1 level did not predict the clinical outcome in patients with early-stage HCC.
We are also aware of several issues in our study that re- 
